These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 31983124)
1. Cetuximab combined with cisplatin improves the prognosis of gastric cancer patients and its effect on P38 MAPK expression. Chen Q; Shen L; Chen C; He H; Fu Y; Xu L; Wang Y J BUON; 2019; 24(6):2490-2498. PubMed ID: 31983124 [TBL] [Abstract][Full Text] [Related]
2. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution. Inal A; Kaplan MA; Kucukoner M; Isikdogan A Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282 [TBL] [Abstract][Full Text] [Related]
3. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer]. Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292 [TBL] [Abstract][Full Text] [Related]
4. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M; Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786 [TBL] [Abstract][Full Text] [Related]
5. Prognostic factors in first-line chemotherapy treated metastatic gastric cancer patients: a retrospective study. Inal A; Kaplan MA; Kuçukoner M; Urakci Z; Guven M; Nas N; Yunce M; Işikdogan A Asian Pac J Cancer Prev; 2012; 13(8):3869-72. PubMed ID: 23098485 [TBL] [Abstract][Full Text] [Related]
6. Phase II trial of neoadjuvant chemotherapy with intraperitoneal paclitaxel, S-1, and intravenous cisplatin and paclitaxel for stage IIIA or IIIB gastric cancer. Shinkai M; Imano M; Chiba Y; Iwama M; Shiraisi O; Yasuda A; Tsubaki M; Nishida S; Kimura Y; Yasuda T J Surg Oncol; 2019 Jan; 119(1):56-63. PubMed ID: 30444009 [TBL] [Abstract][Full Text] [Related]
7. Phase II study on safety and efficacy of Yadanzi® (Javanica oil emulsion injection) combined with chemotherapy for patients with gastric cancer. Liu J; Huang XE; Tian GY; Cao J; Lu YY; Wu XY; Xiang J Asian Pac J Cancer Prev; 2013; 14(3):2009-12. PubMed ID: 23679309 [TBL] [Abstract][Full Text] [Related]
8. [Oxaliplatin combined with capecitabine as first-line chemotherapy for patients with advanced gastric cancer]. Dong NN; Wang MY; Zhang Q; Liu ZF Ai Zheng; 2009 Apr; 28(4):412-5. PubMed ID: 19622303 [TBL] [Abstract][Full Text] [Related]
9. Retrospective analysis of adjuvant intraperitoneal chemotherapy effect prognosis of resectable gastric cancer. Shi C; Yang B; Chen Q; Yang J; Fan N Oncology; 2011; 80(5-6):289-95. PubMed ID: 21778768 [TBL] [Abstract][Full Text] [Related]
10. [Impact of clinicopathological features and extent of lymph node dissection on the prognosis in early gastric cancer patients]. Wu H; Wang L; He YL; Xu JB; Cai SR; Ma JP; Chen CQ; Zhang XH; Zhan WH Zhonghua Zhong Liu Za Zhi; 2013 Jul; 35(7):509-13. PubMed ID: 24257302 [TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study. Bang YJ; Kang YK; Catenacci DV; Muro K; Fuchs CS; Geva R; Hara H; Golan T; Garrido M; Jalal SI; Borg C; Doi T; Yoon HH; Savage MJ; Wang J; Dalal RP; Shah S; Wainberg ZA; Chung HC Gastric Cancer; 2019 Jul; 22(4):828-837. PubMed ID: 30911859 [TBL] [Abstract][Full Text] [Related]
12. The potential for serum p53 to predict the response to chemotherapy of patients with gastric cancer. Zhang J; He XH; Xie XY; Hu X; He C J Int Med Res; 2010; 38(2):423-31. PubMed ID: 20515556 [TBL] [Abstract][Full Text] [Related]
13. Adjuvant radiotherapy for gastric carcinoma: 10 years follow-up of 244 cases from a single institution. Misirlioglu HC; Coskun-Breuneval M; Kucukpilakci B; Ugur VI; Elgin Y; Demirkasimoglu T; Kara SP; Ozgen A; Sanri E; Guney Y Asian Pac J Cancer Prev; 2014; 15(20):8871-6. PubMed ID: 25374221 [TBL] [Abstract][Full Text] [Related]
14. Cutaneous metastases from gastric adenocarcinoma treated with combination chemotherapy producing complete response with long survival. Michiwa Y; Earashi M; Kobayashi H; Matsuki N J Exp Clin Cancer Res; 2001 Jun; 20(2):297-9. PubMed ID: 11484991 [TBL] [Abstract][Full Text] [Related]
15. Improved Survival with Anti-VEGF Therapy in the Treatment of Unresectable Appendiceal Epithelial Neoplasms. Choe JH; Overman MJ; Fournier KF; Royal RE; Ohinata A; Rafeeq S; Beaty K; Phillips JK; Wolff RA; Mansfield PF; Eng C Ann Surg Oncol; 2015 Aug; 22(8):2578-84. PubMed ID: 25582740 [TBL] [Abstract][Full Text] [Related]
16. Is pathologic tumor regression grade after neo-adjuvant chemotherapy a promising prognostic indicator for patients with locally advanced gastric cancer? A cohort study evaluating tumor regression response. Xu X; Zheng G; Zhang T; Zhao Y; Zheng Z Cancer Chemother Pharmacol; 2019 Sep; 84(3):635-646. PubMed ID: 31230156 [TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical expression of vascular endothelial growth factor can predict response to 5-fluorouracil and cisplatin in patients with gastric adenocarcinoma. Takiuchi H; Hirata I; Kawabe S; Egashira Y; Katsu K Oncol Rep; 2000; 7(4):841-6. PubMed ID: 10854555 [TBL] [Abstract][Full Text] [Related]
18. [Multivariate prognostic analysis in gastric carcinoma patients after radical operation]. Zhan YQ; Sun XW; Li W; Chen YB; Xu L; Guan YX; Li YF; Xu DZ Ai Zheng; 2005 May; 24(5):596-9. PubMed ID: 15890105 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of βIII-tubulin and survivin associated with drug resistance to docetaxel-based chemotherapy in advanced gastric cancer. Zheng WE; Chen H; Yuan SF; Wu LL; Zhang W; Sun HY; Chen WJ J BUON; 2012; 17(2):284-90. PubMed ID: 22740207 [TBL] [Abstract][Full Text] [Related]
20. The molecular and clinical verification of therapeutic resistance via the p38 MAPK-Hsp27 axis in lung cancer. Liu CL; Chen SF; Wu MZ; Jao SW; Lin YS; Yang CY; Lee TY; Wen LW; Lan GL; Nieh S Oncotarget; 2016 Mar; 7(12):14279-90. PubMed ID: 26872057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]